Welcome to LookChem.com Sign In|Join Free

CAS

  • or

4687-08-5

Post Buying Request

4687-08-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

4687-08-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 4687-08-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,6,8 and 7 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 4687-08:
(6*4)+(5*6)+(4*8)+(3*7)+(2*0)+(1*8)=115
115 % 10 = 5
So 4687-08-5 is a valid CAS Registry Number.

4687-08-5Relevant articles and documents

Catalytic O-H bond insertion reactions using surface modified sewage sludge as a catalyst

Baell, Jonathan B.,He, Yide,Huang, Fei,Huang, He,Xu, Yao,Yi, Xiangyan,Yu, Yang,Zhang, Zhipeng

, p. 1594 - 1604 (2020/03/26)

Developing a greener, sustainable catalyst is a very important but challenging task in organic synthesis. Herein, for the first time, we choose more economical and greener surface modified sewage sludge-derived carbonaceous materials (SW) treated by perch

On the metabolically active form of metaglidasen: Improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal muscles

Laghezza, Antonio,Montanari, Roberta,Lavecchia, Antonio,Piemontese, Luca,Pochetti, Giorgio,Iacobazzi, Vito,Infantino, Vittoria,Capelli, Davide,De Bellis, Michela,Liantonio, Antonella,Pierno, Sabata,Tortorella, Paolo,Conte Camerino, Diana,Loiodice, Fulvio

, p. 555 - 565 (2015/04/21)

Metaglidasen is a fibrate-like drug reported as a selective modulator of peroxisome proliferator-activated receptor γ (PPARγ), able to lower plasma glucose levels in the absence of the side effects typically observed with thiazolidinedione antidiabetic agents in current use. Herein we report an improved synthesis of metaglidasen's metabolically active form halofenic acid (R)-2 and that of its enantiomer (S)-2. The activity of the two stereoisomers was carefully examined on PPARα and PPARγ subtypes. As expected, both showed partial agonist activity toward PPARγ; the investigation of PPARα activity, however, led to unexpected results. In particular, (S)-2 was found to act as a partial agonist, whereas (R)-2 behaved as an antagonist. X-ray crystallographic studies with PPARγ were carried out to gain more insight on the molecular-level interactions and to propose a binding mode. Given the adverse effects provoked by fibrate drugs on skeletal muscle function, we also investigated the capacity of (R)-2 and (S)-2 to block conductance of the skeletal muscle membrane chloride channel. The results showed a more beneficial profile for (R)-2, the activity of which on skeletal muscle function, however, should not be overlooked in the ongoing clinical trials studying its long-term effects.

METHODS FOR AVOIDING EDEMA IN THE TREATMENT OR PREVENTION OF PPARγ-RESPONSIVE DISEASES, INCLUDING CANCER

-

Page/Page column 71-72, (2008/06/13)

Compounds, compositions, and methods of avoiding edema while treating or preventing PPARγ-mediated diseases, including cancer, using derivatives and prodrugs are provided.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 4687-08-5